NCT03104751 is a clinical trial in Complex Congenital Heart Defect, sponsored by Ohio State University.

Who is sponsoring NCT03104751?

NCT03104751 is sponsored by Ohio State University.

What condition does NCT03104751 study?

NCT03104751 studies Complex Congenital Heart Defect.

Is NCT03104751 still recruiting?

NCT03104751 is currently completed. Last updated 24 February 2021.

Last reviewed 2021-02-24 · How we verify

NCT03104751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurodevelopment in Infants With Complex Congenital Heart Defects

Completed Last updated 24 February 2021

What this trial tests

trial in Complex Congenital Heart Defect in 45 participants. Completed in 24 October 2018.

Timeline

30 June 2016

Primary endpoint
24 October 2018

24 October 2018

Quick facts

Lead sponsor	Ohio State University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	45
Start date	30 June 2016
Primary completion	24 October 2018
Estimated completion	24 October 2018
Sites	1 location across United States

Conditions studied

Complex Congenital Heart Defect — all drugs for Complex Congenital Heart Defect →

Sponsor

Ohio State University

Who can join

Adults 1 Day to 30 Days, any sex, with Complex Congenital Heart Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to systematically describe early neurodevelopment using a complementary set of observational and neurophysiological measures that may predict cognitive and motor delays earlier than currently possible for infants with Complex Congenital Heart Disease (CCHD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Screening and Evaluation of Neurodevelopmental Impairments in Infants Under 6 Months of Age with Congenital Heart Disease.
Tripathi T, Harrison TM, Simsic JM, Cabral TI, et al · · 2022 · cited 6× · PMID 35190880 · DOI 10.1007/s00246-021-02745-4

Verify or expand the search:

Other Ohio State University trials

Trials by the same sponsor.

NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03104751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 24 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing